CollPlant Biotechnologies Ltd
CLGN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CLGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CLGN
CollPlant Biotechnologies Ltd is a clinical-stage regenerative and aesthetic medicine company developing products based on its proprietary recombinant human collagen (rhCollagen) technology, with a current focus on dermal fillers and biofabricated scaffolds.
Key risk: Going concern risk
Market Cap
$6.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
CollPlant Biotechnologies Ltd is a clinical-stage regenerative and aesthetic medicine company developing products based on its proprietary recombinant human collagen (rhCollagen) technology, with a current focus on dermal fillers and biofabricated scaffolds.
- Cash and cash equivalents totaled $5.6 million as of December 31, 2025 [sec · filed 2026-03-26].
- The company has a strategic development agreement with AbbVie for a dermal filler product, which triggered a $10 million milestone payment in June 2023 and a $2 million milestone payment in February 2025 [sec · filed 2026-03-26].
- CollPlant's business model includes in-house development of aesthetic products and biofabricated scaffolds, in-licensing of rhCollagen technology, and co-development with tier-1 partners [sec · filed 2026-03-26].
- The company has a history of significant losses and expects to continue incurring losses for the foreseeable future [sec · filed 2026-03-26].
What works
- CollPlant's rhCollagen technology is positioned as a building block for regenerative medicine applications, with a product pipeline addressing a multi-billion-dollar market [sec · filed 2026-03-26].
- The company has secured milestone payments from AbbVie under a development agreement, demonstrating external validation of its technology [sec · filed 2026-03-26].
- CollPlant's business model includes multiple revenue streams: in-house product development, technology licensing, and co-development partnerships [sec · filed 2026-03-26].
What to weigh
- The company has a history of significant losses and its current cash flow and resources are not sufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern [sec · filed 2026-03-26].
- CollPlant will need to raise additional funding, which may not be available on acceptable terms or at all, and failure to do so could force it to delay, limit, or terminate product development efforts [sec · filed 2026-03-26].
- There is no assurance that further milestone payments under the AbbVie Development Agreement will be received [sec · filed 2026-03-26].
From the filings
Quoted directly from source documents.
Cash position as of December 31, 2025
“The balance of cash and cash equivalents as of December 31, 2025 and 2024 totaled $5.6 million and $11.9 million, respectively.”
SEC filings · March 26, 2026
Milestone payment from AbbVie in February 2025
“In February 2025, we announced an additional achievement of a milestone with respect to dermal filler product under the AbbVie Development Agreement, which triggered a $2 million payment from AbbVie to us.”
SEC filings · March 26, 2026
Going concern risk
“The Company's current cash flow and resources are not sufficient to fund its operation for the next 12 months. Accordingly, the Company's ability to continue as a going concern will require obtaining additional fina”
SEC filings · March 26, 2026
History of significant losses
“We have generally incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.”
SEC filings · March 26, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Current cash flow and resources are insufficient to fund operations for the next 12 months; additional funding is required [sec · filed 2026-03-26].
- Dependence on AbbVie milestones — No assurance of further milestone payments under the AbbVie Development Agreement [sec · filed 2026-03-26].
- History of losses — The company has incurred significant losses since inception and expects to continue losing money [sec · filed 2026-03-26].
- Need for additional capital — May not be able to raise additional funds on acceptable terms, which could force delay or termination of development [sec · filed 2026-03-26].
What to watch
- Ability to secure additional financing to fund operations beyond the next 12 months [sec · filed 2026-03-26].
- Any further milestone achievements or payments under the AbbVie Development Agreement [sec · filed 2026-03-26].
- Progress in preclinical and clinical development of product candidates, including aesthetic and biofabricated scaffold programs [sec · filed 2026-03-26].
- Execution of the contingency plan, including cost reductions, if needed [sec · filed 2025-03-26].
Sources: SEC filings · Generated August 19, 2026 · How we verify sources →
Run CollPlant Biotechnologies Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CollPlant Biotechnologies Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
17
Total value held
$767K
| Holder | Shares | Value |
|---|---|---|
| villere st denis j & co llc | 607,300 | $326K |
| pinnacle associates ltd | 550,229 | $295K |
| brown advisory inc | 118,731 | $64K |
| armistice capital, llc | 64,000 | $34K |
| citadel advisors llc | 32,165 | $17K |
| renaissance technologies llc | 16,800 | $9K |
| xtx topco ltd | 14,795 | $8K |
| waters parkerson & co., llc | 13,250 | $7K |
| two sigma securities, llc | 11,357 | $6K |
| group one trading llc | 1,400 | $749 |
Showing top 10 of 17 institutional holders of CollPlant Biotechnologies Ltd. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.8%
- Days to cover
- 0.5
- Shares short
- 80,466
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CLGN short interestFrequently asked questions
What is the AI investment thesis for CollPlant Biotechnologies Ltd?
CollPlant Biotechnologies Ltd is a clinical-stage regenerative and aesthetic medicine company developing products based on its proprietary recombinant human collagen (rhCollagen) technology, with a current focus on dermal fillers and biofabricated scaffolds.
Who is the CEO of CollPlant Biotechnologies Ltd?
Mr. Yehiel Tal is the chief executive officer of CollPlant Biotechnologies Ltd (CLGN).
Where is CollPlant Biotechnologies Ltd headquartered?
CollPlant Biotechnologies Ltd (CLGN) is headquartered in Rehovot, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.